03 nov: Meddelelse nr. 44/2017: Delårsrapport 1. januar – 30. september 2..
03 nov: Meddelelse nr. 45/2017: Indre værdi pr. 31. oktober 2017
03-11-2017 12:31:46

Genmab's Financial Calendar for 2018

Relateret indhold
14:36 - 
Genmab lancerer ny platform til udvikling af potente an..
11:44 - 
Aktier/middag: Udenlandsk interesse for Pandora presser..
09:18 - 
Aktier/åbning: Danske Bank til bunds i negativt marked
Relateret debat
14:57 - 
Aktien tales langsomt op i Utrecht. Der er flere nyhede..
13:56 - 
Har aktien:   http://ir.genmab.com/events-and-pres..
11:00 - 
Nå.

Company Announcement 

Copenhagen, Denmark; November 3, 2017 – Genmab A/S (Nasdaq Copenhagen: GEN) announces its financial calendar for 2018 as follows: 

EVENT

DATE

Publication of the Annual Report for 2017

Wednesday, February 21, 2018

Annual General Meeting 2018

Tuesday, April 10, 2018

Publication of the Interim Report for the first quarter 2018

Tuesday, May 8, 2018

Publication of the Interim Report for the first half 2018

Wednesday, August 8, 2018

Publication of the Interim Report for the first nine months 2018

Wednesday, November 14, 2018

Shareholders must submit any items for consideration for the agenda of the Annual General Meeting in writing to the Board of Directors no later than Monday, February 26, 2018.

Publication of the financial reports will be after 5:00 PM CET on the date of the event. 

About Genmab

Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer.  Founded in 1999, the company has two approved antibodies, DARZALEX® (daratumumab) for the treatment of certain multiple myeloma indications, and Arzerra® (ofatumumab) for the treatment of certain chronic lymphocytic leukemia indications.  Daratumumab is in clinical development for additional multiple myeloma indications, other blood cancers, and solid tumors.  A subcutaneous formulation of ofatumumab is in development for relapsing multiple sclerosis.  Genmab also has a broad clinical and pre-clinical product pipeline.  Genmab's technology base consists of validated and proprietary next generation antibody technologies - the DuoBody® platform for generation of bispecific antibodies, and the HexaBody® platform which creates effector function enhanced antibodies.  The company intends to leverage these technologies to create opportunities for full or co-ownership of future products. Genmab has alliances with top tier pharmaceutical and biotechnology companies.  For more information visit www.genmab.com.   

Contact:          

Rachel Curtis Gravesen, Senior Vice President, Investor Relations & Communications

T: +45 33 44 77 20; M: +45 25 12 62 60; E: r.gravesen@genmab.com

This Company Announcement contains forward looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.com. Genmab does not undertake any obligation to update or revise forward looking statements in this Company Announcement nor to confirm such statements in relation to actual results, unless required by law.

Genmab A/S and its subsidiaries own the following trademarks: Genmab®; the Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo™; the DuoBody logo®; the HexaBody logo™; HuMax®; HuMax-CD20®; DuoBody®; HexaBody® and UniBody®. Arzerra® is a trademark of Novartis AG or its affiliates. DARZALEX® is a trademark of Janssen Biotech, Inc. 

Company Announcement no. 36

CVR no. 2102 3884

LEI Code 529900MTJPDPE4MHJ122

Genmab A/S

Kalvebod Brygge 43

1560 Copenhagen V

Denmark

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
24 sep
GEN
Der kommer data fra det første DuoBody cMET/EGFR i morgen og der er CMD med en grundig gennemgang af..
15
08:23
GEN
Genmabs CMD bliver vist et hit i dag med bl.a. præsentation af HexElect - ny antistof platform inspi..
14
20 sep
GEN
Være lige opmærksom på vedlagte - CEO er jo supersælger som jo samtidig har noget at have hans posit..
6
24 sep
GEN
Helt desperat at anonyme har omsat for mere end 210 mill. kr. i dag, køb: 204000 salg 187000. Naturl..
5
24 sep
GEN
Ja den er kun steget fra kurs 200 til 1050 paa under 4 aar. Vil ikke blive forbavset hvis den stiger..
3
19 sep
GEN
Har aktien:   GENMAB A/S: GENMAB TO HOST CAPITAL MARKETS DAY 14:59Media Release * Review of Genmabs ..
3
13:56
GEN
Har aktien:   http://ir.genmab.com/events-and-presentations   BB
2
24 sep
GEN
Så undskyld da. Den falder så bare jævnlig.
2
20 sep
GEN
nogen der smider badebukserne
2
20 sep
GEN
Jah men det er nok også mere for at tage noget volumen af bordet for at bygge en ny position op.  Ma..
2

Widex hentede stor fremgang i 2017/18 - NY2

26-09-2018 09:58:19
Den privatejede danske høreapparatkoncern Widex kunne igen i regnskabsåret 2017/18 melde om fremgang i selskabets hovedtal.Omsætningen steg i regnskabsåret, der løb frem til udgangen af april, til 4466 mio. kr. fra 4346 mio. kr. i 2016/17.Det blev omsat til et normaliseret driftsresultat (EBITA) på 901 mio. kr. mod 790 mio. kr. året før.Dermed kan EBITA-marginen opgøres til 20,2 pct. mod 18,2 pct...

Aktier/tendens: Danske Bank igen i vælten på ventet grønt marked

26-09-2018 08:10:16
Det ledende danske aktieindeks, C25, kan onsdag fortsætte tirsdagens positive takter og lægge yderligere til, på en dag hvor Danske Bank endnu engang kan komme i fokus.Bankens aktiekurs steg tirsdag med 2,2 pct. til 170 kr., men banken måtte sent tirsdag eftermiddag se udsigterne for kreditvurderingen hos både Fitch og Standard & Poor's blive sænket til "negative".- De negative udsigter afspejler ..

Danske: Fitch sænker udsigter for kreditvurdering til "negative" - NY

25-09-2018 15:58:53
Fitch Ratings tager kreditvurderingen af Danske Bank op til fornyet overvejelse. Kreditvurderingsinstituttet sænker udsigterne til "negative" fra "stabile".I første omgang fastholder Fitch vurderingen "A". Men i lyset af hvidvasksagen er der mulighed for, at vurderingen af banken sættes ned.Det oplyser Fitch tirsdag.Den negative vurdering afspejler den usikkerhed, der er kommet omkring Danske Bank..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
MHI Vestas/dir: Vi er langt foran konkurrenterne med tocifret havmølle
2
Aktier/tendens: Danske Bank igen i vælten på ventet grønt marked
3
Tirsdagens aktier: Firkløver trak C25 i plus - Pandora faldt til bunds
4
Aktier/middag: Udenlandsk interesse for Pandora presser kursen op
5
Danske Bank/S&P: Sænker udsigter og den selvstædige kreditprofil -GENT

Relaterede aktiekurser

Genmab A/S 1.068,00 0,4% Stigning i aktiekurs

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Berlingske Media 2018  Handelsbetingelser  |  Cookiedeklaration  |  Cookie- og Privatlivspolitik  |  Ophavsret og vilkår
Aktieinformation leveres af Morningstar.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
26. september 2018 15:00:22
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20180919.1 - EUROWEB3 - 2018-09-26 15:00:22 - 2018-09-26 15:00:22 - 1 - Website: OKAY